Proteins IL-17F , Human
- Known as:
- Proteins Interleukin-17F , Human
- Catalog number:
- C030
- Product Quantity:
- 10μg
- Category:
- -
- Supplier:
- Novoprotein
- Gene target:
- Proteins IL-17F Human
Related genes to: Proteins IL-17F , Human
- Gene:
- IL17F NIH gene
- Name:
- interleukin 17F
- Previous symbol:
- -
- Synonyms:
- IL-17F, ML-1, ML1
- Chromosome:
- 6p12.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-03-18
- Date modifiied:
- 2019-04-23
Related products to: Proteins IL-17F , Human
Related articles to: Proteins IL-17F , Human
- Ulcerative colitis (UC) is a kind of hard to cure chronic inflammatory disease. In present work, a series of new costunolide derivatives bearing indole/indoline have been prepared, and anti-inflammatory activities and mechanism have been tested. The results indicated that costunolide derivatives displayed good inhibition of NO generation. The in vivo studies showed that 4c exerted good protective effects in DSS-induced UC mice model by inhibiting the expression of IL-17 A and IL-17F, reducing the infiltration of immune cells, and inhibiting the phosphorylation of JAK2-STAT3 tyrosine residues. Therefore, new costunolide derivatives could be considered as potential JAK2/STAT3 pathway modulator for treatment of UC. - Source: PubMed
Publication date: 2026/04/27
Yang HengliJiang YuanYang RuijuanHuang ZhengxiaoMao ZeweiLi Yanping - Vestibular and oculomotor abnormalities have been widely identified in Fabry disease (FD), with inflammation potentially playing an important role. We aim to investigate the expression of inflammatory cytokines (ICs) in FD patients and their relationship with the vestibular/oculomotor dysfunctions. - Source: PubMed
Publication date: 2026/04/17
Leng YinglinYuan YujingZhao YawenWang XiaMa JingZhang XinyuHuang JingyiHao HongjunZhao GuipingZhang Wei - Canine atopic dermatitis (cAD) is a common inflammatory skin disease with emerging evidence suggesting complex involvement of cytokine patterns including Th17-associated pathways. Gamma delta (γδ) T cells are innate-like lymphocytes capable of rapid interleukin (IL)-17 production, but their role in cAD remains less investigated. This prospective study aimed to localize IL-17F and IL-23 receptor (IL-23R) expression in relation to γδ T cells in the skin of dogs with cAD and to evaluate a SCART1-like RNA probe as a marker for γδ T cells. Skin biopsies were obtained from healthy control dogs (n = 4) and dogs with cAD (n = 5), including non-lesional and lesional sites. RNAscope along with protein co-detection was performed, and signals were quantified using confocal microscopy. cAD dogs had significantly increased dermal γδ T cells, compared to controls (P = 0.0055), with marked dermal enrichment of γδ T cells co-expressing IL-17F (P < 0.001). Epidermal differences between control and cAD were not significant. Similarly, IL-23R co-expression did not differ by disease status; however, epidermal γδ T cell IL-23R expression was inversely associated in lesional skin with owner reported pruritus severity. γδ T cells co-expressing SCART1-like RNA were increased in cAD and strongly correlated with total γδ T cell signal. In conclusion, our findings identify a potential dermal IL-17-associated γδ T cell axis in cAD and provide support for SCART1-like as a marker for canine γδ T cells in future work. Dermal γδ T cells may contribute to chronic inflammation and pruritus in cAD. - Source: PubMed
Publication date: 2026/04/24
Daniels TriciaSparling BrandiDong CharliRosenkrantz WayneMilley CatherineGriffin CraigDrechsler Yvonne - Over the past two decades, experimental and clinical evidence has established the interleukin-23 (IL-23)/interleukin-17 (IL-17) axis as a key mediator of psoriatic inflammation. IL-23, primarily derived from activated dendritic cells, supports the survival and pathogenic function of type 17 immune cells, which subsequently release IL-17A, IL-17F, and IL-22 to promote keratinocyte activation and recruit inflammatory leukocytes. These mechanistic insights have directly translated into the development of highly effective biologic therapies targeting IL-17 or IL-23, substantially improving the management of psoriasis. Beyond injectable biologics, growing efforts to overcome limitations related to long-term adherence, cost, and accessibility have accelerated the development of non-injectable therapeutic approaches. Oral and topical small-molecule agents, including selective tyrosine kinase 2 (TYK2) inhibitors and IL-23 receptor antagonists, are now broadening the therapeutic options. At the same time, progress in molecular engineering, artificial intelligence-guided protein design, and spatial multi-omic technologies are refining therapeutic discovery and enabling more precise targeting of pathogenic immune circuits. In this review, we outline the current understanding of the IL-23/IL-17 pathway in psoriasis pathogenesis and provide a critical overview of approved and emerging therapies directed at this pathway. We also address key biological and translational challenges, including tissue-specific cytokine functions, interspecies differences, and long-term safety considerations, and discuss how these factors may inform future strategies for precision immunotherapy in psoriasis. - Source: PubMed
Publication date: 2026/04/30
Han Sang-JunJung Go-YeonLee Gyeong-CheonKi Dae-HeeKim Byung-Seok - Imiquimod (IMQ)-induced psoriasis-like mouse models are widely used for psoriasis research, but existing methods fail to sustain disease manifestation over time. This study explores the effect of different IMQ dosing frequencies on maintaining psoriasis symptoms in mice. - Source: PubMed
Publication date: 2026/04/23
Zhu HaoyueYu XiaohanWang YazhuoZhao NingQu BaoquanMa HuikeMeng YujiaoZhao JingxiaWang YanLi Ping